Publications
June 2, 2023
We describe improved responses in T-ALL patients during a Phase I dose study (NCT03081910) of autologous CD5-directed chimeric antigen receptor T cell (CD5 CAR T) following the addition of tyrosine kinase inhibitors during manufacturing.
November 13, 2019
We describe a Phase I dose escalation study (NCT03081910) of autologous CD5-directed chimeric antigen receptor T cell (CD5 CAR T) therapy for relapsed or refractory (r/r) T-cell leukemia and lymphoma.
March 5, 2019
In this review, we summarize the preclinical development of CAR-based therapies for T-cell malignancies and discuss strategies to minimize toxicities associated with on-target fratricide and off-tumor activity.
News
September 11, 2023
March Biosciences and CTMC Form Strategic Alliance to Propel Innovative Cancer Cell Therapies
March Biosciences has forged a strategic alliance with CTMC for the development of March Biosciences’ lead asset, MB-105
August 14, 2023
March Biosciences Welcomes Peter Olagunju to its Board of Directors
March Biosciences, a clinical-stage cell therapy company, proudly welcomes Peter Olagunju to its Board of Directors.
June 21, 2023
Portal Innovations to call Houston its third home, with CAR-T startup March Biosciences already in the portfolio
Portal Innovations, a biotech investor and lab operator, is spreading its blueprint to Houston. March Biosciences is one of the firm’s first investments in Texas.